Standard Contracts
DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT BETWEEN PFC THERAPEUTICS, LLC AND BEIJING DOUBLE-CRANE PHARMACEUTICAL CO., LTD.Development, License and Supply Agreement • September 28th, 2005 • Alliance Pharmaceutical Corp • In vitro & in vivo diagnostic substances • New York
DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT Dated as of January 27, 2000 between EURAND AMERICA, NC. Vandalia, Ohio 45377 and RELIANT PHARMACEUTICALS New York, NY 10019 for EXTENDED RELEASE PROPRANOLOLDevelopment, License and Supply Agreement • October 26th, 2007 • Reliant Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIS DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT, dated as of January 27, 2000, between EURAND AMERICA, INC., a corporation organized under the laws of Nevada, with its principal offices at 845 Center Drive, Vandalia, Ohio 45377 (“EURAND”), and RELIANT PHARMACEUTICALS, INC., a corporation organized under the laws of the State of Delaware, with its principal offices at 125 West 55th Street, 11th floor, New York, New York (“RELIANT”);
EX-10.10 9 d641160dex1010.htm EX-10.10 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act...Development, License and Supply Agreement • May 5th, 2020
THIS DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT (this “Agreement”), dated as of August 1st, 2013, is entered into by and between R-Pharm, CJSC, a corporation organized and existing under the laws of the Russian Federation, having offices located at 12 Bld. 1, Nagorny Proezd, Moscow, Russian Federation (“R-Pharm”), and Scynexis, Inc., a corporation organized and existing under the laws of the State of Delaware, having offices located at 3501C Tricenter Boulevard, Durham North Carolina, USA 27713 (“Scynexis”).
EX-10.5 2 dex105.htm FIRST AMENDMENT TO DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT [NOTE: CERTAIN PORTIONS OF THIS DOCUMENT HAVE BEEN MARKED TO INDICATE THAT CONFIDENTIAL INFORMATION HAS BEEN OMITTED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR THIS...Development, License and Supply Agreement • May 5th, 2020
This First Amendment to Development, License and Supply Agreement dated as of June 3, 2010 (this “Amendment”), is entered into by and between Inspire Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware, having offices located at 4222 Emperor Boulevard, Suite 200, Durham, North Carolina 27703, USA (“Inspire”), and Santen Pharmaceutical Co., Ltd., a corporation organized under the laws of Japan, having offices located at 3-9-19 Shimoshinjo, Higashiyodogawa-ku, Osaka, 533-8651, Japan (“Santen”).
DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT dated as of June 18, 2002 between WYETH acting through its Wyeth Consumer Healthcare Division and IMPAX LABORATORIES, INC. for Loratadine/Pseudoephedrine Combination TabletsDevelopment, License and Supply Agreement • January 14th, 2009 • Impax Laboratories Inc • Pharmaceutical preparations • New York
THIS DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT is made and entered into as of this 1st day of June 2002, between WYETH, a corporation organized and existing under the laws of Delaware, acting through its Wyeth Consumer Healthcare Division and having an address at Five Giralda Farms, Madison, New Jersey 07940 (“WCH”) and IMPAX LABORATORIES, INC., a corporation organized and existing under the laws of Delaware and having an address at 3735 Castor Avenue, Philadelphia, Pennsylvania 19124 (“IMPAX”).
AMENDMENT NO. 1 TO DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT Dated as of May 24, 2005 among ETHYPHARM, S.A. 92213 Saint Cloud France and RELIANT PHARMACEUTICALS, INC. Liberty Corner, New Jersey 07938 United StatesDevelopment, License and Supply Agreement • August 5th, 2005 • Reliant Pharmaceuticals, Inc. • Pharmaceutical preparations • New Jersey
AMENDMENT NO. 1 TO DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT (this “Amendment”) is hereby entered into as of May 24, 2005, by and among ETHYPHARM S.A., a corporation organized under the laws of France, with its principal offices at 194 Bureaux de la Colline, 92213 Saint Cloud, France (“ETHYPHARM”), and RELIANT PHARMACEUTICALS, INC., a corporation organized under the laws of the State of Delaware, with its principal offices at 110 Allen Road, Liberty Corner, New Jersey 07938, United States of America, and successor by conversion to Reliant Pharmaceuticals, LLC (“RELIANT”).
AMENDMENT TO DEVELOPMENT, LICENSE AND SUPPLY AGREEMENTDevelopment, License and Supply Agreement • March 29th, 2004 • Immunicon Corp • Laboratory analytical instruments • New York
This Amendment (the "Amendment") is made effective as of the 10th day of December, 2002 by and between ORTHO-CLINICAL DIAGNOSTICS, INC., a New York corporation ("OCD"), and IMMUNICON CORPORATION, a Delaware corporation, and its subsidiaries (collectively, "Immunicon"), to amend the Development, License and Supply Agreement by and between OCD and Immunicon dated as of August 17, 2000 (the "Agreement"). Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Agreement.
EX-10.9 11 d244813dex109.htm AMENDMENT #2 TO AMENDED AND RESTATED DEVELOPMENT, LICENSE, AND SUPPLY AGREEMENT CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “***”. A COMPLETE VERSION OF THE EXHIBIT HAS BEEN FILED...Development, License and Supply Agreement • May 5th, 2020
This Amendment # 2 effective as of the last date on the signature page hereof (“Effective Date”), by and between CIMA LABS INC. (“CIMA”) and Alamo Pharmaceuticals, LLC (“ALAMO”) amends and supplements that certain Amended and Restated Development, License and Supply Agreement between CIMA and ALAMO dated August 22, 2005, as amended by that Amendment #1 to Amended And Restated Development, License and Supply Agreement effective October 19, 2005 (collectively, the “Agreement”).
AMENDED AND RESTATED DEVELOPMENT, LICENSE AND SUPPLY AGREEMENTDevelopment, License and Supply Agreement • March 31st, 2023 • OS Therapies Inc • Pharmaceutical preparations • New York
This Amended and Restated Development, License and Supply Agreement (this “Agreement”) is entered into as of November 13, 2020 (the “Amendment Effective Date”), by and between Advaxis, Inc., a corporation organized under the laws of the State of Delaware, having an address of 305 College Road East, Princeton, NJ 08540 (“Advaxis”), and OS Therapies Incorporated, a corporation organized under the laws of the State of Delaware, having an address of 104 Tech Park Drive Cambridge, MD 21613 (“OST”). Advaxis and OST are each a “party” and, collectively, the “parties.”
EX-10.139 6 d325247dex10139.htm DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT Ex 10.139Development, License and Supply Agreement • May 5th, 2020
The confidential portions of this exhibit have been filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities and Exchange Act of 1934, as amended. REDACTED PORTIONS OF THIS EXHIBIT ARE MARKED BY AN ***.
AMENDED AND RESTATED DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT by and between CIMA LABS INC. And ALAMO PHARMACEUTICALS, LLC dated as of August 22, 2005Development, License and Supply Agreement • November 9th, 2011 • Azur Pharma Public LTD Co • Pharmaceutical preparations • New York
*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.
RECITALSDevelopment, License and Supply Agreement • April 2nd, 2002 • Gen Probe Inc • Services-commercial physical & biological research • New York
EX-10.29 3 d642244dex1029.htm EX-10.29 DEVELOPMENT, LICENSE AND SUPPLY AGREEMENTDevelopment, License and Supply Agreement • May 5th, 2020 • Delaware
THIS DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT (this “Agreement”) is made and entered into as of the latest dated signature on the signature page hereto (the “Effective Date”), and is by and between Watson Laboratories, Inc., a Nevada corporation (“Actavis”), on the one hand, and Merrimack Pharmaceuticals, Inc., a Delaware corporation (“Merrimack”), on the other hand. Actavis and Merrimack shall each sometimes be referred to herein as a “Party” and collectively as the “Parties.”
INTRODUCTIONDevelopment, License and Supply Agreement • April 7th, 2000 • Schein Pharmaceutical Inc • Pharmaceutical preparations
AMENDMENT TO DEVELOPMENT, LICENSE AND SUPPLY AGREEMENTDevelopment, License and Supply Agreement • August 14th, 2000 • Napro Biotherapeutics Inc • Medicinal chemicals & botanical products • Illinois
Dated December 11, 2001 ELAN CORPORATION PLC. AND PAR PHARMACEUTICAL, INC.Development, License and Supply Agreement • January 11th, 2002 • Pharmaceutical Resources Inc • Pharmaceutical preparations • New York
AMENDMENT #8 TO AMENDED AND RESTATED DEVELOPMENT, LICENSE AND SUPPLY AGREEMENTDevelopment, License and Supply Agreement • October 26th, 2011 • Azur Pharma Public LTD Co
This Amendment # 8 effective as of the last date on the signature page hereof (“Amendment Effective Date”), by and between CIMA LABS INC., a Delaware corporation (“CIMA”), and Azur Pharma Limited, an Irish limited company (“AZUR”), as assignee of Azur Pharma International III Limited, a Bermuda corporation, amends and supplements that certain Amended and Restated Development, License and Supply Agreement between CIMA and AZUR dated August 22, 2005, as amended by that Amendment #1 effective October 19, 2005, Amendment #2 effective April 10, 2007, Amendment #3 effective as of January 1, 2008, Amendment #4 effective as of April 15, 2008, Amendment #5 effective as of September 9, 2008, Amendment #6 effective as of March 6, 2009 (“Amendment #6), and Amendment #7 effective as of February 20, 2009 (“Amendment #7) (collectively, the “Agreement”).
AMENDMENT #6 TO AMENDED AND RESTATED DEVELOPMENT, LICENSE AND SUPPLY AGREEMENTDevelopment, License and Supply Agreement • October 26th, 2011 • Azur Pharma Public LTD Co
*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.
AMENDMENT #9 TO AMENDED AND RESTATED DEVELOPMENT, LICENSE AND SUPPLY AGREEMENTDevelopment, License and Supply Agreement • October 26th, 2011 • Azur Pharma Public LTD Co
This Amendment # 9 effective as of the last date on the signature page hereof and upon execution of the Settlement and License Agreement (as defined below) (the “Amendment Effective Date”), by and between CIMA LABS INC., a Delaware corporation (“CIMA”), and Azur Pharma Limited, an Irish limited company (“AZUR”), as assignee of Azur Pharma International III Limited, a Bermuda corporation, amends and supplements that certain Amended and Restated Development, License and Supply Agreement between CIMA and AZUR dated August 22, 2005, as amended by that Amendment #1 effective October 19, 2005, Amendment #2 effective April 10, 2007, Amendment #3 effective as of January 1, 2008, Amendment #4 effective as of April 15, 2008, Amendment #5 effective as of September 9, 2008, Amendment #6 effective as of March 6, 2009 (“Amendment #6), and Amendment #7 effective as of February 20, 2009 (“Amendment #7), and Amendment #8 effective as of March 12, 2010 (“Amendment #8) (collectively, the “Agreement”).
AMENDMENT #1 TO AMENDED AND RESTATED DEVELOPMENT, LICENSE AND SUPPLY AGREEMENTDevelopment, License and Supply Agreement • August 9th, 2006 • Avanir Pharmaceuticals • Pharmaceutical preparations
This Amendment #1 effective as of the last date on the signature page hereof (“Effective Date”), by and between CIMA LABS INC. (“CIMA”) and Alamo Pharmaceuticals, LLC (“ALAMO”) and amends and supplements that certain Amended And Restated Development, License and Supply Agreement between CIMA and ALAMO dated August 22, 2005 (the “Agreement”).
OCTOBER, 23 2009 ELAN PHARMA INTERNATIONAL LIMITED AND JPI COMMERCIAL, LLC AMENDMENT NO. 5 TO THE DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT OFDevelopment, License and Supply Agreement • November 6th, 2009 • Jazz Pharmaceuticals Inc • Pharmaceutical preparations • Georgia
January 27, 2005 Ed Erickson, Chairman and CEO Immunicon Corporation Huntingdon Valley, PA 19006-3574Development, License and Supply Agreement • February 4th, 2005 • Immunicon Corp • Laboratory analytical instruments
Subject: Development, License and Supply Agreement between Immunicon Corporation and Ortho-Clinical Diagnostics, Inc. dated August 17, 2000 and modified on November 10, 2003 and further modified on January 27, 2005.
AMENDMENT TO THE DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT BETWEEN WYETH, ACTING THROUGH ITS WYETH CONSUMER HEALTHCARE DIVISION, AND IMPAX LABORATORIES, INC.Development, License and Supply Agreement • November 12th, 2008 • Impax Laboratories Inc • Pharmaceutical preparations
This Amendment, effective as of the last date of signature appearing below (the “Effective Date”), to the Development, License and Supply Agreement, dated as of June 1, 2002 and amended by letters dated November 19, 2002, April 23, 2003 and May 15, 2003, for Loratadine/Pseudoephedrine Combination Tablets (the “Agreement”) is entered into by and between Wyeth, acting through its Wyeth Consumer Healthcare Division (hereinafter called “WCH”), and Impax Laboratories, Inc. (hereinafter called “Impax”).
LOGO]Development, License and Supply Agreement • May 20th, 2005 • Reliant Pharmaceuticals, Inc.
Upon acceptance by Reliant Pharmaceuticals, LLC, (“Reliant”), this letter will constitute an amendment of the “Development, License and Supply Agreement”, dated May 7, 2001, between Ethypharm and Reliant. The parties agree as follows:
DEVELOPMENT, LICENSE AND SUPPLY AGREEMENTDevelopment, License and Supply Agreement • November 5th, 2009 • Gen Probe Inc • Surgical & medical instruments & apparatus • New York
This DEVELOPMENT, LICENSE, AND SUPPLY AGREEMENT (the “Agreement”) is entered into as of the 16th day of October, 2000 (the “Effective Date”) by and between GEN-PROBE INCORPORATED, a Delaware corporation having a principal place of business at 10210 Genetic Center Drive, San Diego, California 92121 (“Gen-Probe”), and KMC SYSTEMS, INC., a Delaware corporation having a principal place of business at 220 Daniel Webster Highway, Merrimack, New Hampshire (“KMC”), with reference to the following:
December 20, 2005Development, License and Supply Agreement • January 4th, 2006 • Immunicon Corp • Laboratory analytical instruments
Subject: Development, License and Supply Agreement between Immunicon Corporation and Ortho-Clinical Diagnostics, Inc. dated August 17, 2000 as modified.
AMENDMENT #1 TO AMENDED AND RESTATED DEVELOPMENT, LICENSE AND SUPPLY AGREEMENTDevelopment, License and Supply Agreement • October 26th, 2011 • Azur Pharma Public LTD Co
*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.
AMENDMENT #4 TO AMENDED AND RESTATED DEVELOPMENT, LICENSE AND SUPPLY AGREEMENTDevelopment, License and Supply Agreement • October 26th, 2011 • Azur Pharma Public LTD Co
*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.
Byron Hewitt, President and COO Immunicon Corporation Huntingdon Valley, PA 19006-3574Development, License and Supply Agreement • June 21st, 2005 • Immunicon Corp • Laboratory analytical instruments
Subject: Development, License and Supply Agreement between Immunicon Corporation and Ortho-Clinical Diagnostics, Inc. dated August 17, 2000.
DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT dated as of May 7, 2001 among ETHYPHARM, S.A. 92213 Saint Cloud France and ETHYPHARM INDUSTRIES, S.A. 92213 Saint Cloud France and RELIANT PHARMACEUTICALS, LLC Liberty Corner, New Jersey 07938 United StatesDevelopment, License and Supply Agreement • August 5th, 2005 • Reliant Pharmaceuticals, Inc. • Pharmaceutical preparations • New Jersey
THIS DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT, dated as of May 7, 2001, by and among ETHYPHARM S.A., a corporation organized under the laws of France, with its principal offices at 194 Bureaux de la Colline, 92213 Saint Cloud, France, ETHYPHARM INDUSTRIES S.A., a corporation organized under the laws of France, with its principal offices at 194 Bureaux de la Colline, 92213 Saint Cloud, France (Ethypharm, S.A., Ethypharm Industries, S.A., together with their respective subsidiaries and Affiliates, collectively, “ETHYPHARM”), and RELIANT PHARMACEUTICALS, LLC, a limited liability company organized under the laws of the State of Delaware, with its principal offices at 110 Allen Road, Liberty Corner, New Jersey 07938, United States of America (“RELIANT”). Capitalized terms used herein without definition shall have the meanings specified in Section 1 hereof.
RECITALSDevelopment, License and Supply Agreement • September 5th, 2002 • Gen Probe Inc • Services-commercial physical & biological research • New York
DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT dated as of May 7, 2001 among ETHYPHARM, S.A. 92213 Saint Cloud France and ETHYPHARM INDUSTRIES, S.A. 92213 Saint Cloud France and RELIANT PHARMACEUTICALS, LLC Liberty Corner, New Jersey 07938 United StatesDevelopment, License and Supply Agreement • May 20th, 2005 • Reliant Pharmaceuticals, Inc. • New Jersey
THIS DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT, dated as of May 7, 2001, by and among ETHYPHARM S.A., a corporation organized under the laws of France, with its principal offices at 194 Bureaux de la Colline, 92213 Saint Cloud, France, ETHYPHARM INDUSTRIES S.A., a corporation organized under the laws of France, with its principal offices at 194 Bureaux de la Colline, 92213 Saint Cloud, France (Ethypharm, S.A., Ethypharm Industries, S.A., together with their respective subsidiaries and Affiliates, collectively, “ETHYPHARM”), and RELIANT PHARMACEUTICALS, LLC, a limited liability company organized under the laws of the State of Delaware, with its principal offices at 110 Allen Road, Liberty Corner, New Jersey 07938, United States of America (“RELIANT”). Capitalized terms used herein without definition shall have the meanings specified in Section 1 hereof.
AMENDMENT#3 TO AMENDED AND RESTATED DEVELOPMENT, LICENSE AND SUPPLY AGREEMENTDevelopment, License and Supply Agreement • October 26th, 2011 • Azur Pharma Public LTD Co
This Amendment # 3 effective as of the 1st day of January 2008 (“Effective Date”), by and between CIMA LABS INC., a Delaware corporation (“CIMA”), and Azur Pharma International III Limited, a Bermuda corporation (“AZUR”), as assignee of Alamo Pharmaceuticals, LLC, amends and supplements that certain Amended and Restated Development, License and Supply Agreement between CIMA and AZUR dated August 22, 2005, as amended by that Amendment #1 to Amended And Restated Development, License and Supply Agreement effective October 19, 2005 and that Amendment #2 to Amended and Restated Development, License and Supply Agreement effective April 10, 2007 (“Amendment #2) (collectively, the “Agreement”).
AMENDED AND RESTATED DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT by and between CIMA LABS INC. and ALAMO PHARMACEUTICALS, LLC dated as of August 22, 2005Development, License and Supply Agreement • August 9th, 2006 • Avanir Pharmaceuticals • Pharmaceutical preparations • New York
This AMENDED AND RESTATED DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT (this “Agreement”), dated and effective as of August 22, 2005 (the “Effective Date”), is by and between CIMA LABS INC., a Delaware corporation (“CIMA”), and ALAMO PHARMACEUTICALS, LLC, a California Limited Liability Company (“Alamo”).
RUSSIAN TRANSLATION] AMENDMENT to the Development, License and Supply Agreement dated 01 August 2013 MoscowFebruary 19, 2016Development, License and Supply Agreement • November 7th, 2017 • Scynexis Inc • Pharmaceutical preparations
R-PHARM JSC, a joint stock company incorporated and existing under the laws of the Russian Federation and having its principal office at Berzarina street, 19, bld. 1, Moscow, 123154, Russia, Principal State Registration Number (OGRN) 1027739700020 (“R-Pharm”) and
